No Data
No Data
No Data
No Data
No Data
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing
GlobeNewswireApr 29 07:59 ET
Express News | Pasithea Therapeutics Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers
Moomoo 24/7Apr 24 07:59 ET
Pasithea Therapeutics Begins U.S. Trial for Cancer Treatment
InvestingFeb 13 08:04 ET
Pasithea Therapeutics Announces Opening Of Enrollment In The U.S. For Its Phase 1 Trial Of PAS-004
-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy ---- Plans to open three additional sites in Eastern Europe
BenzingaFeb 13 07:59 ET
Top Premarket Decliners
VCI Global (VCIG) shares slumped more than 36% Friday premarket after the company priced a $2.8 million offering of stock and warrants. SEALSQ (LAES) shares tumbled 23%, a day after the company closed
MT NewswiresJan 12 07:43 ET
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients
Pasithea Therapeutics (KTTA) shares rose 12% in recent Tuesday trading after the company got US Federal Drug Administration clearance to assess PAS-004 in cancer patients with advanced solid tumors. P
MT NewswiresJan 2 15:16 ET
Downs Trading : It’s Legal Ketamine. It doesn’t need news to do this heh.
No Data
No Data